June 28, 2019 06:53 AM EDTUpdated July 3, 07:01 AM
Deals
R&D

Eye­ing a drug launch in ear­ly ’20, Es­pe­ri­on lines up a new, $200M fund­ing deal

John Carroll

Editor & Founder

Es­pe­ri­on CEO Tim Mayleben has fat­tened the biotech’s cash re­serves with an ex­tra $200 mil­lion as he lays the foun­da­tion for the pro­ject­ed com­mer­cial launch …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times